Epigenetic silencing of IGFBPL1 promotes esophageal cancer growth by activating PI3K-AKT signaling

Clinical Epigenetics

Table 1 The association of IGFBPL1 methylation and clinical factors in human ESCC

Clinical factor	Number	IGFBPL1 methylation status		P value
Clinical factor	Number	Unmethylated n = 255 50.28%	Methylated n = 246 49.10%	P value
Age (years)				0.167
< 63	252	136	116
≥ 63	249	119	130
Gender				0.102
Male	316	152	164
Female	185	103	82
Tumor size (cm)				0.009**
< 4	254	144	110
≥ 4	247	111	136
Differentiation				0.518
Well or moderate	390	200	190
Poor	111	55	56
Lymph node metastasis				0.131
Negative	310	166	144
Positive	191	89	102
TNM stage				0.012*
Stage I-II	295	164	131
Stage III-VI	206	91	115
Distal metastasis				0.070
Yes	58	36	22
No	443	219	224
Cancer embolus				0.848
Yes	15	8	7
No	486	247	239
Smoking				0.277
Yes	271	144	127
No	230	111	119
Drinking				0.136
Yes	116	52	64
No	385	203	182
Inherited				0.806
Yes	136	68	68
No	365	187	178

ISSN: 1868-7083